Unknown PHASE3 INTERVENTIONAL 2-arm NCT01066351

Efficacy of Erythropoietin to Prevent Acute Kidney Injury in Chronic Kidney Disease Patients Undergoing Cardiac Surgery

Sponsor: Thammasat University

Interventions beta erythropoietin placebo

Updated 5 times since 2017 Last updated: Feb 9, 2010 Started: Jan 31, 2010 Primary completion: Mar 31, 2011 Completion: Jun 30, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Acute Renal Failure, this trial is ongoing. The trial is conducted by Thammasat University and has accumulated 5 data snapshots since 2010. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE3

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE3
Feb 2017 — Jan 2021 [monthly]

Unknown Status PHASE3

Status: Enrolling By Invitation → Unknown Status
Jan 2017 — Feb 2017 [monthly]

Enrolling By Invitation PHASE3

First recorded

Jan 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Thammasat University

Data source: Thammasat University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Khlong Luang, Thailand